Afeez Adekunle Ishola,Nalini Devi Verusingam,Bashir Lawal
Afeez Adekunle Ishola
In 2013, more than a decade ago, the "Recalcitrant Cancer Research Act of 2012" was signed into law in the USA. Recalcitrant cancers are among the leading causes of global cancer morbidity and mortality. At the inception of the act, priorit...
ESR1 mutations in ER-positive breast cancer: from endocrine resistance to ctDNA-guided therapeutic interception [0.03%]
雌激素受体阳性乳腺癌中的ESR1突变：从内分泌耐药到ctDNA导向的治疗干预
Thais Martinez,Samantha Wegner,Hisham F Bahmad
Thais Martinez
Endocrine resistance in estrogen receptor-positive (ER+) breast cancer has undergone a fundamental reconceptualization over the past decade. The discovery that activating mutations in the ESR1 gene encoding ERα emerge under aromatase inhib...
The evolution of chemotherapy in brain tumors: from historical milestones to precision medicine in glioblastoma [0.03%]
脑肿瘤化疗的发展：从历史性的里程碑到胶质母细胞瘤的精准医疗
Alessia Ciafarone,Paola Palumbo
Alessia Ciafarone
Chemotherapy has profoundly shaped modern oncology, evolving from early cytotoxic approaches to biologically informed strategies. In glioblastoma (GBM), the highly aggressive primary brain tumor, precision medicine does not rely on the iden...
Oligometastatic versus polymetastatic colon cancer: functional and genomic determinants of divergent metastatic trajectories [0.03%]
寡转移与多转移型结直肠癌的功能及基因组决定因素：不同的转移轨迹
Roberto Sirica,Carmine Picone,Francesco Sabbatino et al.
Roberto Sirica et al.
Aim: The aim of this study is to investigate the molecular and functional features underlying the clinical heterogeneity between oligometastatic (OM) and polymetastatic (PM) colon cancer. ...
Alhasan Alobaidi,Vikrant Rai
Alhasan Alobaidi
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype defined by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2) expression. Consequently, standard hormone...
The evolving role of targeted radioligand therapy in small cell and non-small cell lung cancer: a systematic review [0.03%]
靶向放射配体治疗在小细胞和非小细胞肺癌中的作用演变：系统性综述
Serin Moghrabi,Saad Ruzzeh,Kamal Al-Rabi et al.
Serin Moghrabi et al.
Background: Targeted radioligand therapy (TRT) is an emerging theranostic modality in oncology. While well established in neuroendocrine and prostate cancers, its role in small cell lung cancer (SCLC) and non-small cell l...
The evolving landscape of first-line and subsequent therapies in EGFR-mutated NSCLC: efficacy, resistance, and tolerability [0.03%]
EGFR突变型NSCLC一线及后续治疗的演变：疗效、耐药和安全性
Carminia Maria Della Corte,Caterina De Rosa,Faiz Ul Haq et al.
Carminia Maria Della Corte et al.
The treatment paradigm for advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations is undergoing a significant transition. While third-generation tyrosine kinase inhibitors (TKIs) like osimertinib have long served as the frontl...
FDA 2025 Cancer Drug Approvals: targeted therapy dominates [0.03%]
美国FDA癌症药物批准趋势（1987-2025）预测：靶向治疗占据主导地位
Jan Trøst Jørgensen
Jan Trøst Jørgensen
This commentary discusses the FDA's drug approvals in 2025, with a particular focus on cancer therapies and the role of companion diagnostics (CDx). Cancer has emerged as the leading therapeutic area, accounting for 35% of all new drug appr...
Solitary fibrous tumor of the lung: diagnostic challenges and surgical management [0.03%]
孤立性纤维瘤的诊断困难及外科治疗经验总结
Vasileios Leivaditis,Konstantinos Grapatsas,Francesk Mulita et al.
Vasileios Leivaditis et al.
Solitary fibrous tumors (SFTs) are rare mesenchymal neoplasms that typically arise from the pleura but may occur in various extrathoracic sites. Primary intraparenchymal pulmonary SFTs without pleural attachment are exceptionally uncommon a...
Lorlatinib in advanced ALK-positive NSCLC after prior progression on ALK inhibitors: real-world experience in Russia [0.03%]
劳拉替尼治疗先前接受过多种ALK抑制剂治疗后病情进展的晚期ALK阳性NSCLC患者：俄罗斯的真实世界经验
Sergey V Orlov,Konstantin K Laktionov,Aram A Musaelyan et al.
Sergey V Orlov et al.
Aim: This study aimed to evaluate the real-world efficacy and safety of lorlatinib in patients with anaplastic lymphoma kinase (ALK)-rearranged metastatic non-small cell lung cancer (NSCLC) after the failure of at least o...